ALX Oncology (NASDAQ:ALXO) Shares Gap Up to $12.14

ALX Oncology Holdings Inc. (NASDAQ:ALXO) gapped up prior to trading on Tuesday . The stock had previously closed at $12.14, but opened at $12.56. ALX Oncology shares last traded at $12.34, with a volume of 25,822 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Stifel Nicolaus reaffirmed a “hold” rating and issued a $14.00 target price (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of ALX Oncology in a research report on Wednesday. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $18.83.

ALX Oncology Trading Down 2.4 %

The company’s fifty day moving average is $13.64 and its two-hundred day moving average is $11.55. The stock has a market cap of $604.31 million, a price-to-earnings ratio of -3.21 and a beta of 1.58. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.05.

ALX Oncology (NASDAQ:ALXO) last issued its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.09). On average, research analysts predict that ALX Oncology Holdings Inc. will post -3.33 EPS for the current fiscal year.

Insider Activity at ALX Oncology

In other news, CEO Jason Lettmann bought 4,400 shares of ALX Oncology stock in a transaction that occurred on Thursday, March 14th. The shares were purchased at an average price of $11.31 per share, with a total value of $49,764.00. Following the completion of the acquisition, the chief executive officer now directly owns 171,620 shares in the company, valued at $1,941,022.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the sale, the insider now owns 628,359 shares in the company, valued at approximately $7,006,202.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jason Lettmann acquired 4,400 shares of ALX Oncology stock in a transaction dated Thursday, March 14th. The shares were bought at an average price of $11.31 per share, with a total value of $49,764.00. Following the transaction, the chief executive officer now directly owns 171,620 shares in the company, valued at approximately $1,941,022.20. The disclosure for this purchase can be found here. 50.30% of the stock is owned by corporate insiders.

Institutional Trading of ALX Oncology

Several institutional investors have recently modified their holdings of ALXO. Vestal Point Capital LP purchased a new stake in shares of ALX Oncology during the 4th quarter worth approximately $24,643,000. Braidwell LP increased its holdings in shares of ALX Oncology by 383.9% in the 1st quarter. Braidwell LP now owns 1,249,900 shares of the company’s stock valued at $5,650,000 after acquiring an additional 991,620 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of ALX Oncology in the 4th quarter valued at $13,605,000. State Street Corp increased its holdings in shares of ALX Oncology by 47.9% in the 1st quarter. State Street Corp now owns 2,133,744 shares of the company’s stock valued at $36,060,000 after acquiring an additional 691,410 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of ALX Oncology in the 4th quarter valued at $8,090,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.